Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca

NCT00128245 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00128245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
December 31, 2006
Enrollment
440
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

keratoconjunctivitis sicca